Christian Nolet's most recent trade in ArriVent BioPharma Inc. was a trade of 15,502 Non-Qualified Stock Option (right to buy) done . Disclosure was reported to the exchange on June 18, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| ArriVent BioPharma Inc. | Christian W. Nolet | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2025 | 15,502 | 15,502 | - | - | Non-Qualified Stock Option (right to buy) | |
| Revance Therapeutics Inc | Christian W. Nolet | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 23,458 | 23,458 | - | - | Stock Option (Right to buy) | |
| Revance Therapeutics Inc | Christian W. Nolet | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 15,000 | 43,606 (0%) | 0% | 0 | Common Stock | |
| ArriVent BioPharma Inc. | Christian W. Nolet | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2024 | 17,884 | 17,884 | - | - | Stock Option (right to buy) | |
| Revance Therapeutics Inc | Christian Nolet | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2023 | 5,915 | 5,915 | - | - | Stock Option (Right to buy) | |
| Revance Therapeutics Inc | Christian Nolet | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2023 | 3,534 | 28,606 (0%) | 0% | 0 | Common Stock | |
| Revance Therapeutics Inc | Christian Nolet | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2022 | 10,756 | 10,756 | - | - | Stock Option (Right to buy) |